SecBot SecBot
424B5 ·Filed Nov 9, 2026

ZBH

ZIMMER BIOMET HOLDINGS, INC.
NEUTRAL
Impact 3/10
Horizonimmediate Processed7d 10h ago SEC0001193125-26-453600
Notable filing: 424B5
Actionable Insight • Neutral

The debt refinancing extends maturities and addresses near-term maturities (Dec 2026 and Feb 2027). Monitor the concurrent euro note offering for completion and total combined proceeds. Watch for any use of proceeds toward share repurchases or M&A, which could signal capital allocation priorities.

DirectionNeutral
Confidencehigh
Horizonimmediate

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+1
Entry
$107.32
T+0 close · Nov 9, 2026 · via day close
Latest settled
+0.14%
T+1 · $107.47 · next T+5 in 4h
Vs SPY
−1.18%
α at T+1
Latest observation
−4.63%
T+4 · FF3 residual α
  1. T+0 · Nov 10 $107.32entry
  2. T+1 · 6d ago +0.14%α −1.18% · $107.47
  3. T+4 · todayOpen
  4. T+5 · in 4h Pending
  5. T+20 · in 22d Pending
  6. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Zimmer Biomet is issuing $500M of 5.850% senior notes due 2036 in an underwritten debt offering, with net proceeds of ~$495.1M to be used for general corporate purposes including potential repayment of near-term maturities (€500M 2.425% notes due Dec 2026 and/or $600M 4.700% notes due Feb 2027), share repurchases, and acquisitions. The offering follows a Q3 earnings report that showed modest revenue growth and raised guidance, and is concurrent with a separate €500M euro note offering.

Key Financial Metrics

Offering Size
$500.0M
Underwriters
Barclays Capital Inc., BofA Securities, Inc. +16

Key Facts

  • $500,000,000 aggregate principal amount of 5.850% notes due 2036
  • Net proceeds estimated at ~$495.1 million after underwriting discount and expenses
  • Notes are unsecured, unsubordinated obligations ranking equally with existing unsecured debt
  • Proceeds may be used to repay portions of €500M 2.425% notes due Dec 2026 and/or $600M 4.700% notes due Feb 2027
  • Concurrent €500M offering of 4.375% notes due 2033 is not contingent on this offering
  • Underwriting discount of 0.650% ($3.25M total); 18 underwriters led by Barclays, BofA, J.P. Morgan, Mizuho, SMBC Nikko
  • Certain underwriters may receive ≥5% of proceeds due to potential debt repayment, triggering FINRA Rule 5121 conflict of interest disclosure
  • Filed 5 days after Q3 2026 earnings (Nov 4) which showed +3.1% revenue growth and raised full-year guidance

Financial Impact

$500M debt issuance; net proceeds ~$495.1M; existing consolidated debt ~$7.5B as of Sep 30, 2026

debtinterest expenseleverage

Risk Factors

  • Notes are structurally subordinated to subsidiary liabilities; no restriction on additional unsecured debt
  • Change of control repurchase event (101% of principal) triggered only if both change of control and below-investment-grade rating event occur
  • No established trading market for the notes; liquidity risk for holders
  • Interest rate increases could reduce market value of fixed-rate notes

Market Snapshot

Exchange
NYSE
Sector
Orthopedic, Prosthetic & Surgical Appliances & Supplies
Analyst Consensus
32% bullish (31 analysts)

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
424B5 Filing (Primary)0001193125-26-453600
Document: d84533dexfilingfees.htm0001193125-26-453600
Document: 0001193125-26-453600-index-headers.html0001193125-26-453600
Document: 0001193125-26-453600-index.html0001193125-26-453600
Document: 0001193125-26-453600.txt0001193125-26-453600

Track record

17 reports on ZBH

Performance horizon

3 of 4 bullish or bearish reports moved the stock their way by T+5. Best: +8.74% at T+60 after the Apr 28, 2026 report. 4 of 4 went positive at some point.

Filters
  1. Nov 12, 20264d ago 8-K Neutral 3/10 Entry $103.21 Now $101.41 −1.74% settles Nov 20
  2. Nov 9, 20267d ago 424B5 Neutral 3/10 Viewing Entry $107.32 Now $101.41 −5.51% settles Nov 17
  3. Nov 9, 20267d ago 424B5 Neutral 3/10 Entry $107.32 Now $101.41 −5.51% settles Nov 17
  4. Nov 5, 202611d ago 424B5 Neutral 3/10 Entry $106.85 to $104.56 Now $101.41 −5.09% ▼ −2.14% −5.43% vs SPY
  5. Nov 5, 202611d ago 424B5 Neutral 2/10 Entry $106.85 to $104.56 Now $101.41 −5.09% ▼ −2.14% −5.43% vs SPY
  6. Nov 4, 202612d ago 8-K Neutral 5/10 Entry $110.15 to $107.47 Now $101.41 −7.93% ▼ −2.43% −1.52% vs SPY
  7. Oct 26, 202621d ago Institutional Cluster Bearish 4/10 Entry $97.44 to $94.52 Now $101.41 −4.07% ▲ +3.00% +1.74% vs SPY
  8. Oct 21, 202627d ago Court Ruling Bearish 6/10 Entry $98.81 to $97.47 Now $101.41 −2.63% ▲ +1.36% +2.06% vs SPY
  9. Sep 15, 20268w ago Insider Cluster Neutral 3/10 Entry $96.53 to $90.64 Now $101.41 +5.06% ▼ −6.10% −8.17% vs SPY
  10. Sep 2, 202610w ago Court Ruling Neutral 2/10 Entry $98.66 to $93.24 Now $101.41 +2.79% ▼ −5.49% −4.34% vs SPY
Showing 10 of 17

US Market Status

Market Closed · Opens in 6h 56m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 9, 2026